Open-Label, Randomized, Phase2 Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Pacritinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Thrombocytopenia
- Focus Therapeutic Use
- Sponsors CTI BioPharma
- 01 Aug 2017 According to a CTI BioPharma media release, this trial was a condition of the clinical hold of pacritinib being removed.
- 01 Aug 2017 According to a CTI BioPharma media release, first patient has been enrolled.
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.